ClinicalTrials.gg
TerminatedNCT04659122Updated Aug 14, 2023

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

A Phase 1 interventional study of AT-100 in COVID-19 and Undefined, sponsored by Airway Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Airway Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Termination / study goals reached

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
1,184th of 1,321
5 · median 91
Started
2021
with 503 others
Phase 1
178 of 1,859
10 open now
Registered
841st of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 1,184th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 178 in phase 1, and was the 841st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired pneumonia.

03

Conditions studied

  • COVID-19
  • Undefined

Keywords

  • COVID-19
  • Mechanical Ventilation
  • Respiratory Support
  • recombinant human Surfactant Protein-D (rhSP-D)
  • Community-acquired Pneumonia
  • CAP
  • zelpultide alfa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is an adult ≥18 years of age.
  2. The subject has documented, laboratory-confirmed SARS-CoV-2 infection within 2 weeks prior to enrollment, or meets criteria for severe community acquired pneumonia (CAP) specified in inclusion 3 below.
  3. The subject has severe SARS-CoV-2 infection requiring intubation and mechanical ventilation. Or, the subject is admitted for severe CAP with respiratory failure as demonstrated by the following:
  1. i. Respiratory failure requiring intubation and mechanical ventilation, and 3. ii. A clinical diagnosis of CAP that includes radiographic findings of new pulmonary infiltrate(s) consistent with CAP plus any one of the following on admission to the hospital: 3. ii. 1. Fever (Temperature > 38.0°C), 3. ii. 2. Hypothermia (Temperature \< 36.0°C), 3. ii. 3. Leukocytosis with White Blood Cells (WBC) > 10,000 cells/µL or immature band forms > 10%, 3. ii. 4. Leukopenia with WBC \< 4,000 cells/µL, or 3. ii. 5. Hypotension Mean Arterial Pressure (MAP) \< 70 mmHg, requiring the initiation of vasopressor support.
  1. The subject has been receiving mechanical ventilation for \<72 hours. 5. The subject is receiving mechanical ventilation due to respiratory disease that is primarily due to SARS-CoV-2 infection or CAP.
  1. The subject, or legally authorized representative if acting on the subject's behalf, is able to provide .

Exclusion criteria

Exclusion Criteria:

  1. The subject refuses to participate, or the subject's legally authorized representative acting on the subject's behalf refuses the subject's participation.
  2. The subject is pregnant or breastfeeding.
  3. The subject is anticipated to be transferred to another hospital that is not a study site within 36 hours of enrollment.
  4. The subject has received or is receiving extracorporeal membrane oxygenation (ECMO) treatment for COVID-19 or CAP treatment.
  5. The subject has (HIV) under highly active antiretroviral therapy (HAART).
  6. The subject has cancer and is receiving chemotherapy treatment at any time during trial duration, or has received chemotherapy treatment within 30 days of trial enrollment.
  7. The subject has a prior history of lung transplant, lobectomy, or other significant lung surgeries that would indicate an already compromised lung.
  8. The subject has known pulmonary air leaks, such as pneumothorax and pneumomediastinum.
  9. Concurrent enrollment in an product, device, or treatment trial or is projected to participate in any other trial that alters the standard of care during the period of this study
  10. The subject has a known allergy, sensitivity, or to any component of the test article (AT-100).
  11. The subject has any active do not resuscitate (DNR)-Comfort Care (CC) order in place. Subjects with an active DNR-Comfort Care Arrest (CCA) are not excluded.
  12. The subject's intubation, re-intubation, or remaining on intubation is not per clinical standard-of-care and is solely for the purposes of administration of study drug.
  13. The subject has any condition or is in a situation in which, in the Investigator's judgement, puts the subject at significant risk, could confound the trial results, or may significantly interfere with the subject's trial participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    AT-100 75 mg

    Once daily AT-100 via intratracheal administration for up to 7 doses.

    Biological: AT-100

  • Experimental
    AT-100 150 mg

    Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe \& tolerated.

    Biological: AT-100

  • Experimental
    AT-100 75 mg or 150 mg (Optional Cohort)

    Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe \& tolerated dose as determined by the prior 2 dosing levels.

    Biological: AT-100

Interventions

  • BiologicalAT-100

    reconstituted AT-100 for intratracheal administration

    Also known as: (rhSP-D)

06

What researchers measure

Primary outcomes

  1. Determining the highest-tolerated & safety-tested AT-100 dose

    Dose escalation of AT-100 will occur to determine the maximum dose (in mg) that produces no significant Dose Limiting Toxicities or dose-related Adverse Events (AEs).

    Time frame: From time of initial AT-100 dosing until the end of the dosing period, up to 7 days

Secondary outcomes

  1. Reduction in mechanical ventilation

    Days on mechanical ventilation.

    Time frame: From mechanical ventilation initiation up to Day 28

Other outcomes

  1. Mortality

    Incidence of death.

    Time frame: Through study completion, up to Day 90

07

Study locations

1 site
  • Airway Therapeutics Investigational Site
    Cincinnati, Ohio 45229, United States
08

References and documents

Publications

  • Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, Khan E, Mehta P, Martin-Gutierrez L, Waddington KE, Robinson GA, Ribeiro Santos L, McLoughlin E, Snell A, Adeney C, Schim van der Loeff I, Baker KF, Duncan CJA, Hanrath AT, Lendrem BC, De Soyza A, Peng J, J'Bari H, Greenwood M, Hawkins E, Peckham H, Marks M, Rampling T, Luintel A, Williams B, Brown M, Singer M, West J, Jury EC, Collin M, Tattersall RS. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020 Oct;2(10):e594-e602. doi: 10.1016/S2665-9913(20)30275-7. Epub 2020 Aug 21. PubMed 32864628 ↗
  • Sorensen GL. Surfactant Protein D in Respiratory and Non-Respiratory Diseases. Front Med (Lausanne). 2018 Feb 8;5:18. doi: 10.3389/fmed.2018.00018. eCollection 2018. PubMed 29473039 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Feb 2023, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2020
First posted
Dec 9, 2020
StartActual
Aug 17, 2021
Primary completionActual
Feb 23, 2023
CompletionActual
Feb 23, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04659122
Lead sponsor
Airway Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Aug 17, 2021
Primary completion
Feb 23, 2023
Completion
Feb 23, 2023
Last update
Aug 14, 2023

Study contacts

Marc O. Salzberg, MD
study chair · Airway Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelpultide alfa

Start the discussion